Modification of Coronary Artery Disease Using Antithrombotic Therapy

Serotonin reuptake inhibitors and cardiovascular disease

“…This association persisted after adjustment for conventional risk factors [10]. 5HT 2A antagonism was advocated in the treatment of coronary artery disease [11] in which some positive preliminary results were published [3] A further aspect of the theory relevant to such a proposal concerns the fact that serotonin is not present in the arterial wall or tissues and does not participate in the mediation of haemostatic platelet layers. Thus, platelet-rich thrombus growth which can cause myocardial infarction and unstable angina are inhibited, but there are no bleeding side effects as seen with all other antiplatelet therapies.…”